Evidence map›Paper›PMID 30125583›Full record

ArticleHuman pathology2018

Laminin 332 expression and prognosis in breast cancer.

Philip M Carpenter, Argyrios Ziogas, Emma M Markham, Alegria S Cantillep, Rui Yan, Hoda Anton-Culver

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Biomaterials for Mimicking and Modelling Tumor Microenvironment.Advances in experimental medicine and biology · 2022
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Philip M CarpenterDepartment of Pathology, Keck School of Medicine, the University of Southern California; Los Angeles, CA, USA; Department of Pathology, University of California, Orange, CA, USA. Electronic address: Philip.Carpenter@med.usc.edu.
Argyrios ZiogasDepartment of Epidemiology, University of California, Irvine, CA 92697-7550, USA. Electronic address: aziogas@uci.edu.
Emma M MarkhamDepartment of Pathology, University of California, Orange, CA, USA; Department of Epidemiology, University of California, Irvine, CA 92697-7550, USA. Electronic address: markhamemma@gmail.com.
Alegria S CantillepDepartment of Pathology, University of California, Orange, CA, USA. Electronic address: alegcantillep@gmail.com.
Rui YanDepartment of Pathology, Keck School of Medicine, the University of Southern California; Los Angeles, CA, USA. Electronic address: ruiyan80@gmail.com.
Hoda Anton-CulverDepartment of Epidemiology, University of California, Irvine, CA 92697-7550, USA.
University of California, Irvine · USUniversity of Southern California · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Christine Hui · 1994 to 2026
$57.9M
HEREDITARY BREAST CANCER--GENETIC AND MOLECULAR STUDIESR01CA058860 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ANTON-CULVER, HODA A · 1994 to 2008
$3.1M
HEREDITARY BREAST CANCER--GENETIC AND MOLECULAR STUDIESU01CA058860 · NCI · UNIVERSITY OF CALIFORNIA IRVINE · PI ANTON-CULVER, HODA A. · 1997 to 2002
$2.5M
NCI NIH HHS P30 CA062203NCI NIH HHS R01 CA058860NCI NIH HHS U01 CA058860
6 · The paper itself

Abstract

The purpose of this study was to determine the distribution of and potential significance of laminin 332 (LM332) in breast cancer. Specimens from a population-based cohort (N = 297) from 1994 to 1995 were stained for estrogen receptor (ER), progesterone receptor (PgR), HER2 and the LM332 β3 chain. Seventy-five tumors were LM332-positive and 222 were negative. LM332 β3 stained 16.0% of ER and/or PgR-positive tumors and 73.2% of triple-negative breast cancers (TNBC). Immunoblotting revealed LM332 in TNBC and HER2-positive samples, but not in an ER-positive breast carcinoma or a phyllodes tumor. After 20 years, 172 patients were alive, 43 had died of breast cancer and 82 of other causes. Patients with LM332-positive tumors had significantly worse 5 (P < .0001) and 10-year (P < .05) overall and breast cancer specific survival. Among patients with LM332 β3-expressing and ER/PgR-negative carcinomas, 10-year survival was significantly reduced (P < .0450). In a multivariate analysis LM332-positive patients had significant hazard ratios of 3.9 with 95% confidence intervals (CI) of 2.0-7.7 and 2.2 with 95% CI of 1.3-3.8 for 5 and 10-year overall survival, respectively. Because tumor cell motility is required for metastasis, the effect of LM332 on MDA-MB-231 migration was determined using siRNA. Knockdown of LM332-specific β3 and γ2 chains reduced motility without affecting viability. Our observation that LM332 in breast carcinoma is associated with decreased survival provides evidence that LM332 may have a role in the aggressive phenotype of some breast cancers.

Indexed as

Cell MovementAdultAgedAged, 80 and overBreast Neoplasms, MaleCarcinomaCell Adhesion MoleculesCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansKalininMaleMiddle AgedNeoplasm InvasivenessPhenotypeCell Adhesion MoleculesKalininBreast carcinomaImmunohistochemistryLaminin 332PrognosissiRNATriple-negativeTumor cell migration

Identifiers

PMID30125583
PMCPMC6289632
OpenAlexW2886238530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.